SimAbs has successfully raised €5 million in a Series A funding round, marking an important milestone in the company’s mission to transform the way antibodies and biosimilars are manufactured.
The round brings together both existing and new strategic investors who support SimAbs’ continuous manufacturing platform and its potential to reshape biologics production at scale. Their confidence reinforces the company’s long-term vision of enabling more efficient and sustainable manufacturing of antibody-based medicines.
With this investment, SimAbs will focus on several key priorities. The company plans to scale its GMP CDMO platform to 50 L and 200 L manufacturing capacity, further advance its biosimilar and antibody development programs, and strengthen strategic partnerships to accelerate commercial growth.
Continuous manufacturing offers several advantages over traditional batch production, including higher productivity, consistent quality, lower cost of goods, and a reduced environmental footprint. As healthcare systems face rising costs and increasing sustainability challenges, innovative production approaches are becoming increasingly important.
Through this new funding round, SimAbs aims to accelerate the development and deployment of its platform, helping bring high-quality and more sustainable antibody manufacturing closer to patients worldwide.
Source:
